Phase
Condition
Diabetic Gastroparesis
Gastroparesis
Treatment
Rifaximin
Placebo
Clinical Study ID
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria
Men and women adult patients, aged 18-75, with diabetic gastroparesis
Diagnosis of diabetic gastroparesis will have been made previously using a combination of symptoms (e.g., nausea, vomiting, bloating, early satiety, abdominal pain), the absence of mechanical obstruction, and delayed gastric emptying using a 4-hour, solid phase scintigraphic study (GES; > 20% remaining at 4 hours)
Exclusion Criteria
Prior surgery to the stomach or esophagus
Known mechanical obstruction of the GI tract
Current or recent (< 4 weeks) use of opioids
Current/active use of cannabis
Current or recent (< 4 weeks) use of antibiotics
Current or recent use of antifungal agents (< 4 weeks)
Prior treatment with rifaximin (< 1 year)
Uncontrolled diabetes with a HgbA1c > 12
Severe uncontrolled or untreated anxiety or depression.
Study Design
Connect with a study center
Mayo Clinic in Florida
Jacksonville, Florida 32224
United StatesSite Not Available
Mayo Clinic in Florida
Jacksonville 4160021, Florida 4155751 32224
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.